Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 972,026
  • Shares Outstanding, K 71,420
  • Annual Sales, $ 55,250 K
  • Annual Income, $ -334,330 K
  • EBIT $ -213 M
  • EBITDA $ -210 M
  • 60-Month Beta 0.48
  • Price/Sales 6.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 103.02% (-7.29%)
  • Historical Volatility 75.79%
  • IV Percentile 20%
  • IV Rank 10.88%
  • IV High 461.32% on 05/07/25
  • IV Low 59.29% on 08/20/25
  • Expected Move (DTE 29) 2.70 (19.24%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 41
  • Volume Avg (30-Day) 206
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 23,909
  • Open Int (30-Day) 24,553
  • Expected Range 11.35 to 16.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +77.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.23 +5.90%
on 01/21/26
18.31 -23.51%
on 12/23/25
-3.87 (-21.63%)
since 12/22/25
3-Month
12.31 +13.77%
on 11/07/25
18.31 -23.51%
on 12/23/25
+0.55 (+4.05%)
since 10/22/25
52-Week
2.21 +533.71%
on 05/08/25
18.31 -23.51%
on 12/23/25
+7.02 (+100.36%)
since 01/22/25

Most Recent Stories

More News
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04,...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.09 (+3.53%)
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...

PHAT : 14.09 (+3.53%)
Cantor Fitzgerald Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Phathom Pharmaceuticals today and set a price target of $29.00. The company’s shares opened today at $12.62.Elevate Your Investing...

PHAT : 14.09 (+3.53%)

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 15.07
2nd Resistance Point 14.63
1st Resistance Point 14.12
Last Price 14.09
1st Support Level 13.16
2nd Support Level 12.72
3rd Support Level 12.21

See More

52-Week High 18.31
Last Price 14.09
Fibonacci 61.8% 12.16
Fibonacci 50% 10.26
Fibonacci 38.2% 8.36
52-Week Low 2.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar